Oryzon Genomics - CRADA win to provide a halo effect
Oryzon has been awarded a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute (NCI) to develop its lead oncology asset, iadademstat. We believe the selection in this highly competitive process provides financial and reputational benefits. This follows positive readouts from the ongoing ALICE study in first-line acute myeloid leukaemia (AML). Oryzon plans to initiate the key follow-on FRIDA study in second line AML in H222. Management also plans to investigate iadademstat in first-line small cell lung cancer (SCLC).
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- Oryzon Genomics - CRADA win to provide a halo effect19 Jul 2022